| http://www.w3.org/ns/prov#value | - The trade-off in invoking the TRIPS compulsory licensing mechanism is between a short term gain to obtain a beneficial treatment at lower cost, and a medium to long term disincentive for the industry to invest in research and development for new drugs, particularly for diseases more prevalent in the third world and emerging economies.
|
